Cite
MLA Citation
Matthew Krebs et al.. “790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC).” Journal for immunotherapy of cancer, vol. 8, n.d., pp. A472–A473. http://access.bl.uk/ark:/81055/vdc_100144718674.0x000004